Journal
WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY
Volume 4, Issue 4, Pages 438-447Publisher
WILEY
DOI: 10.1002/wnan.1168
Keywords
-
Funding
- Interdisciplinary Center for Clinical Research, Wurzburg, Germany [F-25]
- German Research Foundation, Bonn, Germany [SFB 630, B5]
Ask authors/readers for more resources
Inflammation plays a central pathophysiological role in a large number of diseases. While conventional magnetic resonance imaging (MRI) can depict gross tissue alterations due to proton changes, specific visualization of inflammation is an unmet task in clinical medicine. 19F/1H MRI is a novel technology that allows tracking of stem and immune cells in experimental disease models after labelling with perfluorocarbon (PFC) emulsions. 19F markers such as PFC compounds provide a unique signal in vivo due to the negligible 19F background signal of the body. Concomitant acquisition of 1H images places the labelled cells into their anatomical context. This novel imaging technique has been applied to monitor immune cell responses in myocardial infarction, pneumonia, bacterial abscess formation, peripheral nerve injury, and rejection of donor organs after transplantation. Upon systemic application PFC nanoparticles are preferentially phagozytosed by circulating monocytes/macrophages and, thus, the fluorine signal in inflamed organs mainly reflects macrophage infiltration. Moreover, attenuation of the inflammatory response after immunosuppressive or antibiotic treatments could be depicted based on 19F/1H-MRI. Compared to other organ systems 19F-MRI of neuroinflammation is still challenging, mainly because of lack in sensitivity. In focal cerebral ischemia early application of PFCs revealed ongoing thrombotic vessel occlusion rather than cell migration indicating that timing of contrast agent application is critical. Current restrictions of 19F/1H-MRI in sensitivity may be overcome by improved imaging hardware, imaging sequences and reconstruction techniques, as well as improved label development and cell labelling procedures in the future. WIREs Nanomed Nanobiotechnol 2012, 4:438447. doi: 10.1002/wnan.1168 For further resources related to this article, please visit the .
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available